"As part of the Pfizer Agreement, Lpath has granted to Pfizer a time-limited right of first refusal for ASONEP which period ends when the iSONEP Nexus clinical trial is completed." i may have forgotten, but i thought there was a hard and fast date on the option. didnt realize that it was flexible. so this puts off any other prospective partners through mid 2014 (nexus completion) i still say the option on asonep is a buy out strategy by pfizer.
geez, as i type that, it sounds sooooo far off.
also, didnt like this much " The target date to begin testing Lpathomab in clinical trials is in early 2015" no mention of dod. this is gonnal be a long slow grind
Has to be a typo. At least I hope so. I checked the changes to the Pfizer agreement and did not find this listed anywhere. Would hate to think "slight of hand & co." slipped this in on us but definitely would not put it past them based on what we have seen here so far.
General and Administrative Expenses.
General and administrative expenses were $1,004,000 for the quarter ended March 31, 2013 compared to $882,000 for the same period in 2012, an increase of $122,000. This increase is principally attributable to an increase of $70,000 in stock compensation expense in the first quarter of 2013 and the annual NASDAQ listing fee of $32,000.
Ummm, what was that bonus for again?
Speaking of, what happened to the Pancoast peanut gallery? Been awfully quiet lately.